These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 29030675

  • 1. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y, Hihara J, Emi M, Furukawa T, Murakami Y, Nishibuchi I, Ibuki Y, Yamakita I, Kurokawa T, Nagata Y, Okada M.
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [Abstract] [Full Text] [Related]

  • 2. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL, Hsu FM, Tsai CL, Lee JM, Huang PM, Hsu CH, Lin CC, Chang YL, Hsieh MS, Cheng JC.
    Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
    [Abstract] [Full Text] [Related]

  • 3. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Furukawa T, Ibuki Y, Yamakita I, Kurokawa T, Okada M.
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [Abstract] [Full Text] [Related]

  • 4. Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Kim JY, Yun JK, Kim YH, Park SI, Lee JH, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Ahn JY, Kim SB, Cho KJ, Ryu JS, Kim JH, Kang J, Park SR, Kim HR.
    Ann Surg Oncol; 2024 Oct; 31(10):6662-6672. PubMed ID: 38954089
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X, He W, Yang H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Liu H, Yang H, Li T, Zhang X, Li Q, Wang G, Mao T, Guo X, Lin T, Liu M, Fu J, Han Y.
    Ann Surg; 2021 Dec 01; 274(6):e1022-e1029. PubMed ID: 31855875
    [Abstract] [Full Text] [Related]

  • 6. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC, Hsu PK, Chien LI, Liu WC, Huang CS, Hsieh CC, Hsu HS, Wu YC.
    BMC Cancer; 2017 Jan 19; 17(1):62. PubMed ID: 28103913
    [Abstract] [Full Text] [Related]

  • 7. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Nagata Y, Furukawa T, Kurokawa T, Ohsawa M, Okada M.
    Anticancer Res; 2019 Mar 19; 39(3):1433-1440. PubMed ID: 30842179
    [Abstract] [Full Text] [Related]

  • 8. Perineural invasion through the sheath in posttherapy esophagectomy specimens predicts poor survival in patients with esophageal squamous cell carcinoma.
    Tsai CY, Yeh CJ, Chao YK, Chang HK, Tseng CK, Liu YH.
    Eur J Surg Oncol; 2017 Oct 19; 43(10):1970-1976. PubMed ID: 28801062
    [Abstract] [Full Text] [Related]

  • 9. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH, Chen WH, Wen YW, Yeh CJ, Chao YK, Chang HK, Tseng CK, Liu YH.
    Dis Esophagus; 2016 Aug 19; 29(6):634-41. PubMed ID: 26175202
    [Abstract] [Full Text] [Related]

  • 10. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G, Gronnier C, Lebreton G, Brigand C, Mabrut JY, Bail JP, Meunier B, Collet D, Mariette C.
    Ann Surg Oncol; 2015 Dec 19; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [Abstract] [Full Text] [Related]

  • 11. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Furukawa T, Yamakita I, Kurokawa T, Okada M.
    Ann Thorac Surg; 2016 Oct 19; 102(4):1132-9. PubMed ID: 27319990
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G, Zhang C, Sun N, Xue L, Yang Z, Fang L, Zhang Z, Luo Y, Gao S, Xue Q, Mu J, Gao Y, Tan F, He J.
    J Cancer Res Clin Oncol; 2022 Apr 19; 148(4):943-954. PubMed ID: 34013382
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC, Chang JH, Lin WC, Chiou JF, Chang YC, Chang CL, Hsu HL, Chow JM, Yuan KS, Wu ATH, Wu SY.
    Cancer; 2017 Jun 01; 123(11):2043-2053. PubMed ID: 28152166
    [Abstract] [Full Text] [Related]

  • 14. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH, Chao YK, Chang HK, Tseng CK, Chan SC, Liu YH, Chen WH.
    Ann Surg Oncol; 2013 Dec 01; 20(13):4245-51. PubMed ID: 23959050
    [Abstract] [Full Text] [Related]

  • 15. Clinical Significance of 18F-Fluorodeoxyglucose-Positron Emission Tomography-Positive Lymph Nodes to Outcomes of Trimodal Therapy for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Ibuki Y, Murakami Y, Nishibuchi I, Nagata Y, Aoki Y, Furukawa T, Okada M.
    Ann Surg Oncol; 2019 Jun 01; 26(6):1869-1878. PubMed ID: 30675704
    [Abstract] [Full Text] [Related]

  • 16. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H, Tang H, Fang Y, Tan L, Yin J, Shen Y, Zeng Z, Zhu J, Hou Y, Du M, Jiao J, Jiang H, Gong L, Li Z, Liu J, Xie D, Li W, Lian C, Zhao Q, Chen C, Zheng B, Liao Y, Li K, Li H, Wu H, Dai L, Chen KN.
    JAMA Surg; 2021 May 01; 156(5):444-451. PubMed ID: 33729467
    [Abstract] [Full Text] [Related]

  • 17. Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.
    Lin WC, Ding YF, Hsu HL, Chang JH, Yuan KS, Wu ATH, Chow JM, Chang CL, Chen SU, Wu SY.
    Cancer; 2017 Oct 15; 123(20):3904-3915. PubMed ID: 28608916
    [Abstract] [Full Text] [Related]

  • 18. Comparison of pathologic response and survival outcomes between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant immunochemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma: a propensity score-matched analysis.
    Wang Y, Ma K, Zhang H, Wu L, Liu L, Zhou Y, Peng L, Wang Q, Zhuang X.
    BMC Cancer; 2024 Oct 05; 24(1):1228. PubMed ID: 39369225
    [Abstract] [Full Text] [Related]

  • 19. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M, Cook N, Prewett S, Hindmarsh A, Qian W, Gilligan D.
    Dis Esophagus; 2015 Oct 05; 28(7):612-8. PubMed ID: 24863560
    [Abstract] [Full Text] [Related]

  • 20. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
    Huang PM, Hsu FM, Lin CC, Hsu CH, Cheng JC, Lee JM.
    Dig Surg; 2018 Oct 05; 35(2):104-110. PubMed ID: 28675905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.